>
Date: Mon, 15 Jul 2002 13:43:09 -0400
X-Mailer: Microsoft Outlook IMO, Build 9.0.2416 (9.0.2911.0)
For those of you interested in Swiss Biotech, here are some news:
1) Ranking of the most active VC firms in Biotech
The top 10 life sciences investors, compiled by VentureReporter. There is a
number of Swiss VC firms active in the field.
Venture Capital Firm Investments Total Invested
1. Alta Partners 24 $532,050,000.00
2. Novartis BioVentures 17 $384,527,140.00
3. MPM Capital 17 $557,320,000.00
4. 3i 15 $308,850,000.00
5. Forward Ventures 13 $275,000,000.00
6. CDIB Ventures 12 $306,600,000.00
7. J.P. Morgan Partners 12 $383,800,000.00
8. Lombard Odier 12 $256,400,000.00
9. HBM BioVentures 11 $261,900,000.00
10. OrbiMed Advisors
2) New startup company attracts financing
Addex Pharmaceuticals Attracts Venture Funding From Leading European VC
Firms
GENEVA, Switzerland, July 11, 2002: Addex Pharmaceuticals today announced
the closing of a CHF 15.75 million first round (EUR10 million) co-led by
Index Ventures and Sofinnova Partners. Other investors include TVM (Techno
Venture Management), BCV Initiative Capital and individual investors.
Antoine Papiernik, General Partner at Sofinnova, and Richard Rimer, Partner
at Index Ventures, are serving on the board along with highly experienced
pharmaceutical and biotech industry executives.
Addex Pharmaceuticals (www.addexpharma.com) is a biopharmaceutical company
committed to the discovery, development and marketing of novel therapeutic
compounds for the treatment of addiction and other neuropsychiatric
conditions. Addex Pharmaceuticals applies a new scientific approach that
fully integrates molecular, behavioral and chemistry technologies to address
drug dependence. "Addiction is a large under-served market and significant
public health issue. Addex Pharmaceuticals is targeting this market with a
focus on nicotine, alcohol, cocaine and opiate dependence," remarked
Francois Conquet, CEO of Addex Pharmaceuticals. "We will also explore other
indications related to the addiction process including anxiety and
depression."
Additional information at http://www.addexpharma.com/news.html
3) Six spinoffs companies present at BIO 2003
For the second year, SNI (Swiss Network of Innovation) invited six spinoffs
active in biotech to present their activities at BIO 2003, an industry
tradeshow gathering more than 15,000 research specialists andbusiness
executives. The entrepreneurs participated to several match-making events,
got meetings with potential partners and collected tons of interesting
contacts. The list of companies is below. Let me know if you want me to
connect you to any of them:
- CELLnTEC: dedicated to producing a new standard of naturally immortal,
untransformed animal cell cultures. www.cellntec.com
- GLYCART biotechnology: active in the research, development and
commercialization of new potent antibody-based products for the treatment of
unmet clinical needs such as cancer. www.glycart.com
- Xigen: development of peptide drugs http://www.xigen.ch
- Athelas: identification and development of novel anti-virulence drugs and
related products www.athelas.com
- Ayanda Biosystems: development of a high-performance cell-based platform
for high-throughput reliable screening (HTRS) assays in drug discovery and
cell-based proteomics http://www.ayanda-biosys.com
-- Pascal Marmier
_____________________________________
Pascal Marmier
SHARE - Swiss House Boston
Consulate of Switzerland
Advisor, Innovation & Entrepreneurship
420 Broadway
Cambridge, MA 02138
Direct: (617) 876-3076 ext. 13
Fax: (617) 876-3079
Cell: (617) 331-3989
EMail: pascal_at_creativeswitzerland.com
Web: www.CreativeSwitzerland.com and
www.sni-rsi.ch
______________________________________
=================================================================
To unsubscribe from the startup mailing list send the
message body of "unsubscribe startup" to majordomo_at_swiss-list.com
or visit http://www.swiss-list.com/mailings/
Received on Mon Jul 15 2002 - 19:12:06 PDT
